NLS Pharmaceutics AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NLSP research report →
About the company
NLS Pharmaceutics AG is a biopharmaceutical firm dedicated to researching and creating treatments for intricate and uncommon conditions affecting the central nervous system. Its primary focus includes advancing medications for narcolepsy, idiopathic hypersomnia, and various other unusual sleep conditions, alongside neurodevelopmental challenges like attention deficit hyperactivity disorder (ADHD). Key experimental compounds in its pipeline are Quilience, designed to address excessive daytime sleepiness and cataplexy, and Nolazol, which targets ADHD.
- CEO
- Alexander Zwyer
- IPO
- 2021
- Employees
- 6
- HQ
- Zurich, CH
Price Chart
- Market Cap
- $919.60K
- P/E
- -0.42
- P/S
- 0.00
- P/B
- 1.79
- EV/EBITDA
- 0.04
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 41.94%
- ROIC
- -75.27%
- Revenue
- $0 · 0.00%
- Net Income
- $-1,980,810 · 83.73%
- EPS
- $-26.30 · -721.88%
- Op Income
- $-4,380,113
- FCF YoY
- 55.89%
- 52W High
- $43.40
- 52W Low
- $0.76
- 50D MA
- $18.99
- 200D MA
- $19.40
- Beta
- 0.13
- Avg Volume
- 74.12K
Get TickerSpark's AI analysis on NLSP
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our NLSP coverage
Recent articles, reports, and earnings notes.
No research on NLSP yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NLSP report →Similar companies
Peers in the same neighborhood.